Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of IV Posaconazole in Chinese Subjects
NCT03336502Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of posaconazole in invasive fungal infection (IFI), sponsored by Merck & Co. Primary endpoints: Steady State Average Concentration at Day 10, Percentage of Participants With ssCavg >= 500 ng/mL at Day 10 and 6 more. Started Dec 2017; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT03336502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03336502.